A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.

Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,446 · see citing works

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1× · see citing works

The many faces of tau

Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · see citing works

Alzheimer's disease

López, J. A., González, H. M., & Léger, G. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 834 · see citing works

Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease

Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654 · see citing works

Alzheimer’s Disease: Past, Present, and Future

Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771700100x · Cited by 649 · see citing works

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633 · see citing works

Tau and tauopathies

Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609 · see citing works

Tau Kinetics in Neurons and the Human Central Nervous System

Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works

Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction

Tai, H.-C., & Schuman, E. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2499 · Cited by 532 · see citing works

Tau degradation: The ubiquitin–proteasome system versus the autophagy-lysosome system

Lee, M. J., Lee, J. H., & Rubinsztein, D. C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.03.001 · Cited by 364 · see citing works

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

Ghosh, A. K., & Osswald, H. L. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60460h · Cited by 361 · see citing works

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310 · see citing works

Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant

Sydow, A., Van der Jeugd, A., Zheng, F., Ahmed, T., Balschun, D., Petrova, O., Drexler, D., Zhou, L., Rune, G., Mandelkow, E., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-10.2011 · Cited by 302 · see citing works

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283 · see citing works

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory

Fà, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M. A., Puma, D. D. L., Chatterjee, I., Li, J., Saeed, F., et al. (2016) · Scientific Reports · doi:10.1038/srep19393 · Cited by 274 · see citing works

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · see citing works

Tauopathies.

(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00025-0 · Cited by 225 · see citing works

Overactivation of glycogen synthase kinase‐3 by inhibition of phosphoinositol‐3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory

Liu, S. J., Zhang, A. H., Li, H. L., Wang, Q., Deng, H. M., Netzer, W. J., Xu, H., & Wang, J. Z. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02070.x · Cited by 224 · see citing works

Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice

Ma, Q., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Teng, E., Hu, S., Chen, P., Maiti, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393751 · Cited by 212 · see citing works

Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies

Sengupta, U., Guerrero‐Munoz, M. J., Castillo‐Carranza, D. L., Lasagna‐Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., Krishnamurthy, S., Farhed, M., Jackson, G. R., & Kayed, R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.019 · Cited by 181 · see citing works

PROTACs– a game-changing technology

Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 167 · see citing works

Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology

Robinson, M. J., Lee, B. Y., & Hane, F. T. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161149 · Cited by 165 · see citing works

A role for tau in learning, memory and synaptic plasticity

Biundo, F., Prete, D. D., Zhang, H., Arancio, O., & D'adamio, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-21596-3 · Cited by 149 · see citing works

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

Jin, J., Wu, Y., Chen, J., Shen, Y., Zhang, L., Zhang, H., Chen, L., Yuan, H., Chen, H., Zhang, W., et al. (2020) · Theranostics · doi:10.7150/thno.46985 · Cited by 146 · see citing works

Investigational BACE inhibitors for the treatment of Alzheimer’s disease

Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132 · see citing works

The Dynamics and Turnover of Tau Aggregates in Cultured Cells

Guo, J., Buist, A., Soares, A. C., Callaerts, K., Calafate, S., Stevenaert, F., Daniels, J. P., Zoll, B. E., Crowe, A., Brunden, K. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712083 · Cited by 80 · see citing works

Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease

Wilson, B., & Geetha, K. M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.044 · Cited by 65 · see citing works

Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau

Li, X., Lei, P., Tuo, Q., Ayton, S., Li, Q., Moon, S., Volitakis, I., Liu, R., Masters, C. L., Finkelstein, D. I., et al. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0378-2 · Cited by 63 · see citing works

LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy

Guo, X., Sun, G., Zhou, T., Wang, Y., Xu, X., Shi, X., Zhu, Z., Rukachaisirikul, V., Hu, L., & Shen, X. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.128 · Cited by 47 · see citing works

Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology

Robinson, M., Lee, B. Y., & Hanes, F. T. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-179007 · Cited by 41 · see citing works

Combined Effect of Fatty Diet and Cognitive Decline on Brain Metabolism, Food Intake, Body Weight, and Counteraction by Intranasal Insulin Therapy in 3×Tg Mice

Sanguinetti, E., Guzzardi, M. A., Panetta, D., Tripodi, M., Sena, V. D., Quaglierini, M., Burchielli, S., Salvadori, P. A., & Iozzo, P. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00188 · Cited by 32 · see citing works

Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28 · see citing works

Administration of NaHS Attenuates Footshock-Induced Pathologies and Emotional and Cognitive Dysfunction in Triple Transgenic Alzheimer’s Mice

Huang, H.-J., Chen, S.-L., & Hsieh‐Li, H. M. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00312 · Cited by 21 · see citing works

Overexpression of SNX7 reduces Aβ production by enhancing lysosomal degradation of APP

Xu, S., Zhang, L., & Brodin, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.127 · Cited by 15 · see citing works

Chemical Methods to Knock Down the Amyloid Proteins

Gao, N., Chen, Y., Zhao, Y., & Li, Y. (2017) · Molecules · doi:10.3390/molecules22060916 · Cited by 14 · see citing works

Cornel iridoid glycoside induces autophagy to protect against tau oligomer neurotoxicity induced by the activation of glycogen synthase kinase-3β

Yang, C., Li, X., Zhang, L., Li, Y., Li, L., & Zhang, L. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01318-3 · Cited by 13 · see citing works

Wortmannin inhibits K562 lukemic cells by regulating PI3k/Akt channel in vitro

Wu, Q., Chen, Y., Cui, G., et al. (2009) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-009-0412-x · Cited by 11 · see citing works

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · see citing works

Tau-targeting therapies for Alzheimer disease: Current status and future directions

Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100 · see citing works

Tau; One Protein, So Many Diseases

Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33 · see citing works

Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease

Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22 · see citing works

Targeted protein modification as a paradigm shift in drug discovery

Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18 · see citing works

[Construction of stable expression of human thyrotropin receptor alpha-subunits on HEK 293T cells].

Tang, G. (2014) · PubMed

Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes

Farout, L., Mary, J., Vinh, J., Szweda, L. I., & Friguet, B. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.02.003 · Cited by 127 · see citing works

The Proteasome as a Drug Target

Mizushima, T., & Tsukihara, T. (2003) · Methods and principles in medicinal chemistry · doi:10.1002/3527601872.ch3

Assays of proteasome activity in relation to aging

Rivett, A. J., Bose, S., Pemberton, A. J., et al. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00127-4 · Cited by 33 · see citing works

Implication of altered proteasome function in alcoholic liver injury

Natalia, N., Osna, Terrence, et al. (2007) · Acta Scientiarum Naturalium Universitatis Sunyatseni